BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36661679)

  • 1. Pathology of Cholangiocarcinomas.
    Guedj N
    Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in Diagnosing and Reporting Cholangiocarcinoma.
    El Jabbour T; Molnar A; Lagana SM
    Surg Pathol Clin; 2023 Sep; 16(3):599-608. PubMed ID: 37536891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.
    Nakanuma Y; Sato Y
    J Hepatobiliary Pancreat Sci; 2014 Jul; 21(7):441-7. PubMed ID: 24446421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma.
    Sarcognato S; Sacchi D; Fassan M; Fabris L; Cadamuro M; Zanus G; Cataldo I; Capelli P; Baciorri F; Cacciatore M; Guido M
    Pathologica; 2021 Jun; 113(3):158-169. PubMed ID: 34294934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathology of cholangiocarcinoma].
    Guedj N; Bedossa P; Paradis V
    Ann Pathol; 2010 Dec; 30(6):455-63. PubMed ID: 21167432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
    Goeppert B
    Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
    Ilyas SI; Gores GJ
    Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
    Patil PA; Taddei T; Jain D; Zhang X
    Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diagnosis of intrahepatic cholangiocarcinoma.
    Haga H; Patel T
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
    Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
    Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathways of genetic transformation in cholangiocarcinogenesis.
    Serafini FM; Radvinsky D
    Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.